Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Terbinafine
Drug ID BADD_D02160
Description Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues.[A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]
Indications and Usage For the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).
Marketing Status OTC; Discontinued; Prescription
ATC Code D01AE15; D01BA02
DrugBank ID DB00857
KEGG ID D02375
MeSH ID D000077291
PubChem ID 1549008
TTD Drug ID D01AYJ
NDC Product Code 72189-243; 63187-213; 69097-859; 59349-0008; 70518-1191; 76282-209; 62135-572; 71335-1668; 71205-152
Synonyms Terbinafine | Terbinafine, (Z)-isomer | Terbinafine, (Z)- | Lamisil | (E)-N-(6,6-Dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride | TDT-067 | TDT 067 | TDT067 | DA 5505 | SF 86-327 | SF 86 327 | SF 86327 | SF-86-327 | SF86327 | Terbinafine Hydrochloride
Chemical Information
Molecular Formula C21H25N
CAS Registry Number 91161-71-6
SMILES CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Restlessness19.11.02.002; 17.02.05.0210.002117%
Rhabdomyolysis15.05.05.0020.004939%
Saliva altered07.06.01.0040.000706%Not Available
Salivary hypersecretion07.06.01.0090.000706%Not Available
Schizophrenia19.03.04.0010.000706%Not Available
Seizure17.12.03.001--
Sepsis11.01.11.003--
Serum sickness-like reaction08.01.03.003; 10.01.03.005--Not Available
Shock24.06.02.0020.000460%Not Available
Sinus bradycardia02.03.03.0090.000706%
Skin disorder23.03.03.0070.000706%Not Available
Skin exfoliation23.03.07.0030.008467%Not Available
Skin hyperpigmentation23.05.01.0030.001411%
Skin infection23.09.04.002; 11.01.12.0030.001058%
Skin lesion23.03.03.0100.001764%Not Available
Skin reaction23.03.03.013; 10.01.03.0190.001411%Not Available
Skin ulcer24.04.03.007; 23.07.03.0030.001058%
Sleep disorder19.02.04.001--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.0200.003881%
Stomatitis07.05.06.005--
Stress19.06.02.0040.001411%Not Available
Subcutaneous abscess23.09.04.003; 11.01.12.0070.001058%Not Available
Suicidal ideation19.12.01.0030.003881%
Swelling08.01.03.0150.003528%Not Available
Swelling face23.04.01.018; 10.01.05.0180.001411%Not Available
Swollen tongue10.01.05.015; 07.14.02.003; 23.04.01.0140.000706%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.001764%
Systemic lupus erythematosus10.04.03.004; 15.06.02.003; 23.03.02.0060.002822%Not Available
Systemic lupus erythematosus rash23.03.13.007; 15.06.02.005; 10.04.03.0050.000736%Not Available
Tachycardia02.03.02.007--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 13 Pages